Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 16, 2026

Aible Launches SafeClaw Long-Running Agents and Presents at Eight Partner Booths and Sessions at NVIDIA GTC 2026

View original at finance.yahoo.com
Aible Launches SafeClaw Long-Running Agents and Presents at Eight Partner Booths and Sessions at NVIDIA GTC 2026 Aible launches SafeClaw that enables long-running agents with built-in enterprise AI governance and guardrails…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We built our first Aible AI agent running on NVIDIA DGX Spark in 5 minutes. The ROI on Aible agents will be immediate. By reducing attorney response time on research questions we save a few hundred dollars per hour per attorney, the AI agent pays for itself within days

    60% confidence
  • Running on our NVIDIA DGX Spark in a secure air-gapped environment allows me to prototype confidently, eliminate surprise spending, and scale as we prove the ROI from each use case

    60% confidence
  • The end-to-end serverless AI platform is up to 200X more cost efficient

    60% confidence
  • What stood out was the model accuracy, because Aible eliminated hallucinations compared to other AI platforms we evaluated

    60% confidence
  • We have extensive experience running Aible agents in production and have seen firsthand how they can safely drive measurable operational impact at scale. Our proactive patient rescheduling agent has expanded from a single department to seven clinical service lines in just over a year, meaningfully improving patient access to timely care

    60% confidence
  • Enterprise long-running agents can unlock significant value - particularly across silo'd core systems - but require the kind of IT governance and model monitoring enabled by Aible SafeClaw and NVIDIA NeMo Guardrails

    60% confidence
  • Aible SafeClaw takes a different approach where users can test the plan generated by the long-running agent at setup time, approve which tools and models it can use and when, approve exactly which data sources it can access and how, and then approve that plan for ongoing operations

    60% confidence
  • Each tool that Aible SafeClaw leverages is completely deterministic and logged in the customer environment as Python code

    60% confidence
  • This project used the Aible software environment together with an NVIDIA DGX Spark / Dell Pro Max GB10 system to conduct exploratory analyses on locally stored health‑related data. We ran all model components on the standalone device so that data remained within institutional control. After internal validation, the analytical agent created on the local system was automatically transferred to the Nebius cloud environment without transferring underlying research data

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com